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Improved access to healthcare, vaccines and treatment with antibiotics has reduced global mortality from childhood
community-acquired pneumonia. However, as respiratory viruses are responsible for most episodes of pneumonia,
important questions remain over who should receive these agents and the length of each treatment course. Worldwide
concerns with increasing antibiotic resistance in respiratory pathogens and appeals for more prudent antibiotic
prescribing provide further urgency to these clinical questions. Unfortunately, guidelines for treatment duration in
particular are based upon limited (and often weak) evidence, resulting in national and international guidelines
recommending treatment courses for uncomplicated pneumonia ranging from 3 to 10 days. The advantages of short-
course therapy include a lower risk of developing antibiotic resistance, improved adherence, fewer adverse drug effects,
and reduced costs. The risks include treatment failure, leading to increased short- or long-term morbidity, or even
death. The initial challenge is how to distinguish between bacterial and non-bacterial causes of pneumonia and then to
undertake adequately powered randomised-controlled trials of varying antibiotic treatment durations in children who
are most likely to have bacterial pneumonia. Meanwhile, healthcare workers should recognise the limitations of current
pneumonia treatment guidelines and remember that antibiotic course duration is also determined by the child’s
response to therapy.
Keywords: Pneumonia, Antibiotics, ChildCommunity-acquired pneumonia is the leading global
cause of childhood morbidity and mortality. Annually,
there are an estimated 120–160 million clinical pneumonia
episodes worldwide, causing 14 million hospitalisations
and almost one million deaths in children aged <5 years
[1, 2]. Although respiratory viruses are the most common
pathogens associated with childhood pneumonia, most
deaths are attributed to Streptococcus pneumoniae and
Haemophilus influenzae type b [3]. Consequently, antibi-
otics have reduced pneumonia-related morbidity and mor-
tality. Nevertheless, several knowledge gaps exist with
prescribing antibiotics for pneumonia, including the opti-
mal length of treatment required. These limitations are
evident in both national and international guidelines,
which have had to rely upon expert opinion and weak
levels of evidence from a small number of clinical trials
with substantial methodological limitations [4–7]. A good* Correspondence: k.grimwood@griffith.edu.au
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tions provided on treatment duration for uncomplicated
childhood pneumonia [5, 6]. This raises several questions
for healthcare workers when determining how long they
should be giving antibiotics to a child with pneumonia.What factors influence decisions on antibiotic
duration?
Several factors are considered when both choosing an
antibiotic to treat a suspected case of bacterial pneumo-
nia and determining how long it should be given. These
include: (i) clinical presentation and severity; (ii) as-
sumed bacterial aetiology based upon the child’s age,
vaccination status, underlying co-morbidities and the
local pathogen antibiotic susceptibility profiles; and (iii)
cost, availability, tolerability, and ease of administration
(e.g. frequency and palatability) of the chosen agent that
may influence treatment adherence.
In clinical practice, the optimal duration of antibiotic
treatment depends upon whether the pneumonia is
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disorders are present (e.g. malnutrition, human immuno-
deficiency virus infection, or chronic cardiopulmonary dis-
ease); the nature of the causative pathogen, adequacy of
source control, and the patient’s response to treatment.
In uncomplicated pneumonia the advantages of a
short-treatment course include a lower risk of develop-
ing antibiotic resistance, improved adherence, fewer ad-
verse effects, and decreased costs [6, 8]. The main
danger though of shortened therapy in young children is
treatment failure from delayed or incomplete eradication
of the infecting pathogen(s), risking additional morbidity
and injury to the developing lungs and possibly a greater
chance of impaired lung function, chronic obstructive
pulmonary disease and bronchiectasis later in life [9].
It is really bacterial pneumonia?
Most studies on antibiotic duration were undertaken in
low- and low-to-middle-income countries where the
burden of pneumonia is greatest. Unfortunately, the
diagnosis of bacterial pneumonia in these settings is also
the most uncertain as it relies upon healthcare workers
following clinical algorithms without adequate labora-
tory and radiographic support. Furthermore, no diagnos-
tic gold standard for pneumonia exists, and there are
major difficulties differentiating between viral and bac-
terial pneumonia clinically and radiographically, let
alone obtaining an accurate microbiological cause [10].
What are the current recommendations and what are
their limitations?
As most childhood pneumonia deaths occur out of hos-
pital in the low-resource settings of sub-Saharan Africa
and Southern Asia, the diagnostic algorithms used by
the World Health Organization (WHO) are designed to
reduce mortality, sacrificing specificity for sensitivity [4].
Otherwise healthy children with suspected clinical pneu-
monia are managed as outpatients and receive either
3 days of high-dose oral amoxicillin (80–90 mg/kg/day)
if tachypnoeic alone, or 5 days if subcostal recession is
also present [4]. Those with severe clinical pneumonia
accompanied by danger signs (e.g. dehydration, seizures,
or altered consciousness) receive parenteral penicillin
(or ampicillin) and gentamicin as first-line agents for at
least 5 days. These recommendations are based upon
several large randomised controlled trials (RCTs) of oral
vs. parenteral antibiotics and 3 vs. 5 days of oral anti-
biotic treatment in children from developing countries
[7, 11]. A recent systematic review published in the jour-
nal [7] found three RCTs from developing countries
comparing short (3 days) vs. standard (5 days) oral anti-
biotic treatments in children with non-severe (tachyp-
noea alone) pneumonia. These studies were conducted
in either India or Pakistan and each involved >2000children aged 2–59 months [12–14]. Each reported that
3 days was either equivalent [12] or not statistically dif-
ferent [13, 14] to 5 days treatment. However, the validity
of these three studies is questionable. The follow-up was
limited to only 14 days and although failure rates ranged
from 9.5 % to 21 %, just a single death occurred in a 3-
month old infant amongst the 6197 trial subjects, a much
lower case fatality than expected for pneumonia in these
settings [2, 3]. Almost half the subjects were infants, as
many as 22 % had wheeze, and pneumonia was diagnosed
following the WHO clinical algorithm [4]. Only one study
included chest radiographs [12], where just one in seven
children with clinical pneumonia had abnormal radio-
graphic findings. Consequently, these studies of treating
non-severe pneumonia in developing countries are limited
by inherent biases towards equivalence of varying treat-
ment durations, since many (if not most) participating sub-
jects were unlikely to benefit from antibiotics as they had
bronchiolitis, viral pneumonia, or virus-associated wheeze.
Indeed, a recent double-blind RCT in 900 children aged
2–59 months from Pakistan with WHO-diagnosed non-
severe pneumonia found equivalent clinical outcomes in
those receiving either 3 days of oral amoxicillin or placebo
with cumulative treatment failure rates by day 5 of 13.5 %
and 17.6 %, respectively, while once again no deaths were
reported [15].
In contrast to developing countries, criteria for diagnos-
ing childhood pneumonia in developed nations often re-
quire chest radiographic confirmation, especially for
hospitalised cases [5]. Nevertheless, little information is
available guiding treatment duration [6, 7], although a re-
cent small, single-centre, three-arm RCT from Israel of 140
non-hospitalised children aged <5 years with likely bacter-
ial pneumonia (based on clinical criteria, chest radio-
graphic consolidation, and raised white blood cell counts)
found that the 40 % failure rate of a 3 day course of amoxi-
cillin was unacceptably high, while no failures were re-
ported in those receiving either a 5 or 10 days course of
the antibiotic [16]. These data help support current na-
tional guidelines from developed countries recommending
at least 5 days of antibiotics for children suspected of bac-
terial pneumonia [5, 6].
So, what is required?
The guidelines for the treatment duration of pneumonia
are based upon limited and often weak evidence [4–7].
The situation is not helped by the important knowledge
gaps that still remain regarding how to best identify chil-
dren with pneumonia, including how to reliably differen-
tiate between bacterial and non-bacterial causes [10].
Healthcare workers in resource poor settings in particu-
lar need access to validated, simple, and inexpensive
point-of-care diagnostic tests. Unfortunately, none are
likely to be available soon. While new technologies such
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for identifying aetiological pathogens in pneumonia, these
and other molecular-based platforms are unlikely to be
made available in the foreseeable future to low- and
middle-income countries where the burden of pneumonia
is greatest. Meanwhile, although there is mounting global
concern over rising rates of antibiotic resistance resulting
in increased calls for shorter treatment courses, it is im-
portant to remember that an ineffective short antibiotic
treatment course for pneumonia is still the worst strategy
when either it is not needed (e.g. for viral respiratory infec-
tions) or when it results in treatment failure, risking death,
increased morbidity and/or long-term sequelae [8–10].
Clearly, more robust evidence for antibiotic treatment
duration for pneumonia is needed. A good start would be
to undertake additional RCTs in sub-Saharan Africa and
Asia (where feasible sample sizes are possible), recruiting
subjects with a greater probability of bacterial infection
(based on clinical severity or radiographic criteria). Mean-
while, healthcare workers should recognise the limitations
of current “one size fits all” pneumonia treatment guide-
lines and remember that the duration of antibiotic therapy
is also determined by individual host and pathogen factors
and how the child responds to treatment.
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